- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00063635
Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC) (TONIC)
August 27, 2012 updated by: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Clinical Research Network in Nonalcoholic Steatohepatitis: Treatment of Nonalcoholic Fatty Liver Disease in Children (TONIC)
The purpose of this study is to determine if therapeutic modification of insulin resistance or oxidative stress leads to improvement in serum or histologic indicators of liver injury or quality of life.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
173
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
San Diego, California, United States, 92103
- University of California, San Diego
-
San Francisco, California, United States, 94143
- University of California, San Francisco
-
-
District of Columbia
-
Washington, District of Columbia, United States, 20010
- Children's National Medical Center
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Indiana University
-
-
Maryland
-
Baltimore, Maryland, United States, 21205
- Johns Hopkins University
-
-
Missouri
-
St. Louis, Missouri, United States, 63110
- St. Louis University
-
-
Ohio
-
Cleveland, Ohio, United States, 44109
- Case Western Reserve University
-
-
Texas
-
Houston, Texas, United States, 77030
- Texas Children's Hospital
-
-
Virginia
-
Richmond, Virginia, United States, 23298
- Virginia Commonwealth University
-
-
Washington
-
Seattle, Washington, United States, 98195
- University of Washington
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
8 years to 17 years (Child)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
- Age 8-17 years at first screening visit
- Histologic evidence of Nonalcoholic Fatty Liver Disease (NAFLD) - biopsy cannot be older than 6 months as of randomization
- ALT level >60 U/L at time of screening and on one previous occasion determined at least one month but no greater than 6 months prior to screening ALT
- Consent
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: 3
Matching placebo
|
Twice daily
|
Active Comparator: 1
Metformin, 500 mg, twice daily
|
500 mg, twice daily
|
Active Comparator: 2
Vitamin E, 400 IU, twice daily
|
400 IU, twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Participants With Sustained Reduction in Alanine Aminotransferase (ALT) to Either 50% of Baseline Value or < 40 IU/L
Time Frame: baseline and 96 weeks
|
The primary outcome was sustained reduction in ALT level, defined as 50% or less of the baseline level or 40 IU/L or less at each visit from 48 to 96 weeks of treatment.
|
baseline and 96 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Serum Aspartate Aminotransferase (AST)
Time Frame: baseline and 96 weeks
|
baseline and 96 weeks
|
|
Change in Nonalcoholic Fatty Liver Disease (NAFLD) Score (Histologic Feature Scores Determined by Standardized Scoring of Liver Biopsies) From Baseline at 96 Weeks of Treatment
Time Frame: baseline and 96 weeks
|
Histological activity was assessed using the NAFLD activity score on a scale of 0 to 8, with higher scores indicating more severe disease; the components of this measure include steatosis (0-3), lobular inflammation (0-3), and hepatocellular ballooning (0-2).
|
baseline and 96 weeks
|
Number of Participants With Improvement in Liver Fibrosis Score
Time Frame: baseline and 96 weeks
|
Fibrosis is assessed on a scale of 0 to 4 with higher scores indicating more severe fibrosis.
This secondary outcome measure is the number of participants that experienced a decrease in fibrosis score at 96 weeks compared to baseline, which indicates improvement in fibrosis.
|
baseline and 96 weeks
|
Number of Participants With Improvement in Steatosis Score
Time Frame: baseline and 96 weeks
|
Steatosis is assessed on a scale of 0 to 3 with higher scores indicating more severe steatosis.
This secondary outcome measure is the number of participants that experienced a decrease in steatosis score at 96 weeks compared to baseline, which indicates improvement in steatosis.
|
baseline and 96 weeks
|
Number of Participants With Improvement in Lobular Inflammation Score
Time Frame: baseline and 96 weeks
|
Lobular inflammation is assessed on a scale of 0 to 3 with higher scores indicating more severe lobular inflammation.
This secondary outcome measure is the number of participants that experienced a decrease in lobular inflammation score at 96 weeks compared to baseline, which indicates improvement in lobular inflammation.
|
baseline and 96 weeks
|
Number of Participants With Improvement in Ballooning Degradation Score
Time Frame: baseline and 96 weeks
|
Ballooning is assessed on a scale of 0 to 2 with higher scores indicating more severe ballooning.
This secondary outcome measure is the number of participants that experienced a decrease in ballooning score at 96 weeks compared to baseline, which indicates improvement in ballooning.
|
baseline and 96 weeks
|
Change in Body Mass Index
Time Frame: baseline and 96 weeks
|
baseline and 96 weeks
|
|
Change in Serum Vitamin E Levels
Time Frame: baseline and 96 weeks
|
Change in alpha-Tocopherol
|
baseline and 96 weeks
|
Change in Quality of Life (QOL) Scores- Physical Health
Time Frame: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
Change in QOL- Psychosocial Health
Time Frame: baseline and 96 weeks
|
Change in self-reported QOL physical health Pediatric Quality of Life Inventory (version 4.0) scores were recorded to range from 0 to 100 with increasing scores indicating better quality of life.
|
baseline and 96 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Guerrerio AL, Colvin RM, Schwartz AK, Molleston JP, Murray KF, Diehl A, Mohan P, Schwimmer JB, Lavine JE, Torbenson MS, Scheimann AO. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am J Clin Nutr. 2012 Apr;95(4):892-900. doi: 10.3945/ajcn.111.020156. Epub 2012 Feb 15.
- Corey KE, Vuppalanchi R, Vos M, Kohli R, Molleston JP, Wilson L, Unalp-Arida A, Cummings OW, Lavine JE, Chalasani N; Nonalcoholic Steatohepatitis Clinical Research Network. Improvement in liver histology is associated with reduction in dyslipidemia in children with nonalcoholic fatty liver disease. J Pediatr Gastroenterol Nutr. 2015 Mar;60(3):360-7. doi: 10.1097/MPG.0000000000000584.
- Lavine JE, Schwimmer JB, Van Natta ML, Molleston JP, Murray KF, Rosenthal P, Abrams SH, Scheimann AO, Sanyal AJ, Chalasani N, Tonascia J, Unalp A, Clark JM, Brunt EM, Kleiner DE, Hoofnagle JH, Robuck PR; Nonalcoholic Steatohepatitis Clinical Research Network. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA. 2011 Apr 27;305(16):1659-68. doi: 10.1001/jama.2011.520.
- Lavine JE, Schwimmer JB, Molleston JP, Scheimann AO, Murray KF, Abrams SH, Rosenthal P, Sanyal AJ, Robuck PR, Brunt EM, Unalp A, Tonascia J; Nonalcoholic Steatohepatitis Clinical Research Network Research Group. Treatment of nonalcoholic fatty liver disease in children: TONIC trial design. Contemp Clin Trials. 2010 Jan;31(1):62-70. doi: 10.1016/j.cct.2009.09.001. Epub 2009 Sep 15.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2005
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
February 1, 2010
Study Registration Dates
First Submitted
July 1, 2003
First Submitted That Met QC Criteria
July 2, 2003
First Posted (Estimate)
July 3, 2003
Study Record Updates
Last Update Posted (Estimate)
September 27, 2012
Last Update Submitted That Met QC Criteria
August 27, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- NASH - PEDIATRICS (IND)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fatty Liver
-
Shiraz University of Medical SciencesCompletedFatty Liver | Fatty Liver, NonalcoholicIran, Islamic Republic of
-
Hoffmann-La RocheCompletedFatty Liver, Non-alcoholic Fatty Liver Disease, NAFLDGermany, Austria
-
GenfitTerminatedNon-Alcoholic Fatty LiverNetherlands
-
Medical College of WisconsinENDRA Life Sciences, Inc.RecruitingFatty Liver | NAFLD | Non-Alcoholic Fatty Liver Disease | Non-alcoholic Steatohepatitis | Non-alcoholic Fatty Liver | NASH | Fatty Liver DiseaseUnited States
-
Cairo UniversityRecruitingNon-Alcoholic Fatty Liver DiseaseEgypt
-
Miriam Vos, MDImmuron Ltd.; Advanced MR Analytics ABCompletedNonalcoholic Fatty Liver Disease (NAFLD)United States
-
Nehal Abou SeadaCompletedNon-Alcoholic Fatty Liver Disease
-
HaEmek Medical Center, IsraelTerminatedPatients With Fatty Liver DiseaseIsrael
-
AB Biotics, SACompletedNon Alcoholic Fatty LiverMexico
-
University of L'AquilaRecruitingNAFLD- Non Alcoholic Fatty Liver DiseaseItaly
Clinical Trials on Metformin
-
Anji PharmaSuspendedDiabetes Mellitus, Type 2Spain, United States, Canada, Hungary, Brazil, Czechia, Poland, Bulgaria
-
ShionogiCompleted
-
NuSirt BiopharmaCompletedType 2 Diabetes MellitusUnited States
-
Bristol-Myers SquibbCompletedType 2 Diabetes MellitusSouth Africa, United States, Canada, Puerto Rico, Hungary, Germany, Czechia, Poland, Romania, United Kingdom
-
Charles University, Czech RepublicCompleted
-
Hoffmann-La RocheCompletedDiabetes Mellitus Type 2United States, Mexico, Argentina
-
Hadassah Medical OrganizationWithdrawn
-
Woman'sPfizer; American Cancer Society, Inc.; Our Lady of the Lake Regional Medical...WithdrawnInsulin Resistance | Breast Cancer Stage | Racial BiasUnited States
-
Garvan Institute of Medical ResearchWeizmann Institute of ScienceActive, not recruitingType 2 Diabetes Mellitus | Pre DiabetesAustralia
-
University Hospital, Basel, SwitzerlandCompletedBecker's Muscular Dystrophy (BMD)Switzerland